Search This Blog

Monday, September 13, 2021

Silverback Therapeutics to Present Data from Phase 1/1b Clinical Trial at ESMO 2021

  Interim monotherapy and initial pembrolizumab combination data from the dose-escalation arm of the SBT6050-101 trial will be reported –

– Conference call to be held on Thursday, September 16, 2021, at 6:30 AM ET –

Conference Call and Webcast on Thursday, September 16, 2021, at 6:30 AM ET

Silverback’s management team will host a conference call on Thursday, September 16, 2021, at 6:30 AM ET following the release of the poster at the ESMO 2021 Virtual Congress. A live webcast, including slides, can be accessed through the Events section of the Company’s website at https://ir.silverbacktx.com/news-events/events. An archived replay will be available shortly after the conclusion of the event.

https://finance.yahoo.com/news/silverback-therapeutics-present-data-phase-120000703.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.